Sunesis Pharmaceuticals (FRA:RYIS) Days Inventory : 0.00 (As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Sunesis Pharmaceuticals's Average Total Inventories for the three months ended in Dec. 2020 was €0.00 Mil. Sunesis Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2020 was €0.00 Mil.

The historical rank and industry rank for Sunesis Pharmaceuticals's Days Inventory or its related term are showing as below:

FRA:RYIS's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 192.54
* Ranked among companies with meaningful Days Inventory only.

Sunesis Pharmaceuticals's Days Inventory stayed the same from Dec. 2019 (0.00) to Dec. 2020 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sunesis Pharmaceuticals Days Inventory Historical Data

The historical data trend for Sunesis Pharmaceuticals's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Days Inventory Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Days Inventory

Get a 7-Day Free Trial

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sunesis Pharmaceuticals's Days Inventory

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunesis Pharmaceuticals's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Days Inventory distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Days Inventory falls into.

Sunesis Pharmaceuticals Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sunesis Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2020 is calculated as

	Days Inventory (A: Dec. 2020 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2019 )	+	Total Inventories (A: Dec. 2020 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2020 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Sunesis Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2020 is calculated as:

	Days Inventory (Q: Dec. 2020 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2020 )	+	Total Inventories (Q: Dec. 2020 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2020 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Sunesis Pharmaceuticals (FRA:RYIS) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sunesis Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2020 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sunesis Pharmaceuticals's Inventory to Revenue for the three months ended in Dec. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Sunesis Pharmaceuticals Days Inventory Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines